Investigating CYP3A-mediated Drug-Drug Interactions With BTK Degraders

Phase 1 data show that BGB-16673 is eliminated through intestinal and biliary excretion, limiting CYP3A-mediated interactions.

Investigating CYP3A-mediated Drug-Drug Interactions With BTK Degraders

Episodes

Specialty:

All

Year:

All

Please check back later for more content.

Trending on OncLive

FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma

Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma

Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC

The OncFive: Top Oncology Articles for the Week of 8/9

FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma